Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results

Amgen said its investigational biosimilar treatment for moderate-to-severe rheumatoid arthritis demonstrated clinical equivalence in safety and effectiveness with AbbVie’s Humira after 24 weeks in a phase III study.

Source: WSJ.com: Health - February 3, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news